Synthetic and biological studies of carbasugar SGLT2 inhibitors

Wai Lung Ng, Tony Kung Ming Shing

Research output: Contribution to journalArticle

Abstract

Type 2 diabetes mellitus (T2DM) is the most common type of diabetes. Unfortunately, current therapeutic agents are not so effective that only less than 36% of the patients have been treated satisfactorily. Thus, we set out to investigate novel small-molecule carbohydrate mimics as potential antidiabetic agents to supplement the existing medication. Selective inhibition of the transporter protein sodium-glucose cotransporter 2 (SGLT2) has emerged as a promising way to control blood glucose level in T2DM patients. We have pioneered the design and synthesis of some novel carbasugars (pseudosugars), readily available from inexpensive D-glu-conolactone, which contains a metabolically stable-pseudo-glycosidic" C-O bond. Their aza-analogues (with a C-N bond) and carbon-analogues (with a C-C bond) have been prepared to provide important insights into the structure-activity relationship (SAR) of these inhibitors, thereby aiding the development of carbasugar SGLT2 inhibitors as potential antidiabetic agents. Our synthetic targets are the carbocyclic analogues of sergliflozin and dapagliflozin, which are readily accessible via various transition metal-catalyzed crosscoupling reactions. We herein describe our novel synthetic approaches towards carbasugar SGLT2 inhibitors, and discuss their SAR.

Original languageEnglish
Pages (from-to)1215-1222
Number of pages8
JournalYuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry
Volume76
Issue number11
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Carbasugars
Sodium-Glucose Transport Proteins
Medical problems
Hypoglycemic Agents
Transition metals
Blood Glucose
Carbon
Carbohydrates
Molecules
Proteins

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Synthetic and biological studies of carbasugar SGLT2 inhibitors. / Ng, Wai Lung; Shing, Tony Kung Ming.

In: Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry, Vol. 76, No. 11, 01.01.2018, p. 1215-1222.

Research output: Contribution to journalArticle

Ng, Wai Lung ; Shing, Tony Kung Ming. / Synthetic and biological studies of carbasugar SGLT2 inhibitors. In: Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry. 2018 ; Vol. 76, No. 11. pp. 1215-1222.
@article{e0af8310af3145caa73d97274f17776b,
title = "Synthetic and biological studies of carbasugar SGLT2 inhibitors",
abstract = "Type 2 diabetes mellitus (T2DM) is the most common type of diabetes. Unfortunately, current therapeutic agents are not so effective that only less than 36{\%} of the patients have been treated satisfactorily. Thus, we set out to investigate novel small-molecule carbohydrate mimics as potential antidiabetic agents to supplement the existing medication. Selective inhibition of the transporter protein sodium-glucose cotransporter 2 (SGLT2) has emerged as a promising way to control blood glucose level in T2DM patients. We have pioneered the design and synthesis of some novel carbasugars (pseudosugars), readily available from inexpensive D-glu-conolactone, which contains a metabolically stable-pseudo-glycosidic{"} C-O bond. Their aza-analogues (with a C-N bond) and carbon-analogues (with a C-C bond) have been prepared to provide important insights into the structure-activity relationship (SAR) of these inhibitors, thereby aiding the development of carbasugar SGLT2 inhibitors as potential antidiabetic agents. Our synthetic targets are the carbocyclic analogues of sergliflozin and dapagliflozin, which are readily accessible via various transition metal-catalyzed crosscoupling reactions. We herein describe our novel synthetic approaches towards carbasugar SGLT2 inhibitors, and discuss their SAR.",
author = "Ng, {Wai Lung} and Shing, {Tony Kung Ming}",
year = "2018",
month = "1",
day = "1",
doi = "10.5059/yukigoseikyokaishi.76.1215",
language = "English",
volume = "76",
pages = "1215--1222",
journal = "Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry",
issn = "0037-9980",
publisher = "Society of Synthetic Organic Chemistry",
number = "11",

}

TY - JOUR

T1 - Synthetic and biological studies of carbasugar SGLT2 inhibitors

AU - Ng, Wai Lung

AU - Shing, Tony Kung Ming

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Type 2 diabetes mellitus (T2DM) is the most common type of diabetes. Unfortunately, current therapeutic agents are not so effective that only less than 36% of the patients have been treated satisfactorily. Thus, we set out to investigate novel small-molecule carbohydrate mimics as potential antidiabetic agents to supplement the existing medication. Selective inhibition of the transporter protein sodium-glucose cotransporter 2 (SGLT2) has emerged as a promising way to control blood glucose level in T2DM patients. We have pioneered the design and synthesis of some novel carbasugars (pseudosugars), readily available from inexpensive D-glu-conolactone, which contains a metabolically stable-pseudo-glycosidic" C-O bond. Their aza-analogues (with a C-N bond) and carbon-analogues (with a C-C bond) have been prepared to provide important insights into the structure-activity relationship (SAR) of these inhibitors, thereby aiding the development of carbasugar SGLT2 inhibitors as potential antidiabetic agents. Our synthetic targets are the carbocyclic analogues of sergliflozin and dapagliflozin, which are readily accessible via various transition metal-catalyzed crosscoupling reactions. We herein describe our novel synthetic approaches towards carbasugar SGLT2 inhibitors, and discuss their SAR.

AB - Type 2 diabetes mellitus (T2DM) is the most common type of diabetes. Unfortunately, current therapeutic agents are not so effective that only less than 36% of the patients have been treated satisfactorily. Thus, we set out to investigate novel small-molecule carbohydrate mimics as potential antidiabetic agents to supplement the existing medication. Selective inhibition of the transporter protein sodium-glucose cotransporter 2 (SGLT2) has emerged as a promising way to control blood glucose level in T2DM patients. We have pioneered the design and synthesis of some novel carbasugars (pseudosugars), readily available from inexpensive D-glu-conolactone, which contains a metabolically stable-pseudo-glycosidic" C-O bond. Their aza-analogues (with a C-N bond) and carbon-analogues (with a C-C bond) have been prepared to provide important insights into the structure-activity relationship (SAR) of these inhibitors, thereby aiding the development of carbasugar SGLT2 inhibitors as potential antidiabetic agents. Our synthetic targets are the carbocyclic analogues of sergliflozin and dapagliflozin, which are readily accessible via various transition metal-catalyzed crosscoupling reactions. We herein describe our novel synthetic approaches towards carbasugar SGLT2 inhibitors, and discuss their SAR.

UR - http://www.scopus.com/inward/record.url?scp=85056315620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056315620&partnerID=8YFLogxK

U2 - 10.5059/yukigoseikyokaishi.76.1215

DO - 10.5059/yukigoseikyokaishi.76.1215

M3 - Article

AN - SCOPUS:85056315620

VL - 76

SP - 1215

EP - 1222

JO - Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry

JF - Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry

SN - 0037-9980

IS - 11

ER -